| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
87,080,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases. Co.'s compound, batoclimab, is a human, monoclonal antibody targeting the neonatal fragment crystallizable receptor. Co.'s product candidate, batoclimab, has been dosed in small volumes (e.g., two mL) and with a 27-gauge needle, while still generating therapeutically relevant pharmacodynamic activity. Co. is developing batoclimab for Myasthenia Gravis, Thyroid Eye Disease and Warm Autoimmune Hemolytic Anemia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
1,526,316 |
1,977,983 |
| Total Buy Value |
$0 |
$0 |
$58,000,008 |
$60,700,210 |
| Total People Bought |
0 |
0 |
1 |
3 |
| Total Buy Transactions |
0 |
0 |
1 |
4 |
| Total Shares Sold |
128,507 |
210,980 |
524,708 |
685,584 |
| Total Sell Value |
$3,769,867 |
$6,942,921 |
$14,218,474 |
$16,695,946 |
| Total People Sold |
7 |
10 |
10 |
10 |
| Total Sell Transactions |
16 |
30 |
51 |
75 |
| End Date |
2024-02-27 |
2023-11-26 |
2023-05-28 |
2022-05-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Butchko Julia G. |
Chief Development Officer |
• – – |
2023-10-05 |
4 |
S |
$35.54 |
$62,885 |
D/D |
(1,735) |
414,525 |
|
- |
|
| Salzmann Peter |
Chief Executive Officer |
• • – |
2023-10-05 |
4 |
S |
$35.54 |
$189,887 |
D/D |
(5,239) |
964,726 |
|
- |
|
| Roivant Sciences Ltd. |
|
• • • |
2023-10-02 |
4 |
B |
$38.00 |
$58,000,008 |
D/D |
1,526,316 |
79,805,331 |
0.01 |
- |
|
| Roivant Sciences Ltd. |
|
• • • |
2023-10-02 |
4 |
A |
$38.00 |
$169,999,992 |
D/D |
4,473,684 |
78,279,015 |
|
- |
|
| Levine Mark S. |
Chief Legal Officer |
• – – |
2023-08-24 |
4 |
S |
$20.30 |
$249,406 |
D/D |
(12,286) |
314,488 |
|
- |
|
| Macias William L. |
Chief Medical Officer |
• – – |
2023-08-24 |
4 |
S |
$20.30 |
$250,360 |
D/D |
(12,333) |
337,392 |
|
- |
|
| Butchko Julia G. |
Chief Development Officer |
• – – |
2023-08-24 |
4 |
S |
$20.30 |
$250,360 |
D/D |
(12,333) |
416,260 |
|
- |
|
| Barnett Eva Renee |
Chief Financial Officer |
• – – |
2023-08-24 |
4 |
S |
$20.30 |
$292,036 |
D/D |
(14,386) |
335,477 |
|
- |
|
| Salzmann Peter |
Chief Executive Officer |
• • – |
2023-08-14 |
4 |
S |
$21.34 |
$2,207,178 |
D/D |
(103,058) |
1,026,739 |
|
- |
|
| Salzmann Peter |
Chief Executive Officer |
• • – |
2023-08-07 |
4 |
S |
$21.73 |
$2,202,096 |
D/D |
(101,339) |
1,129,797 |
|
- |
|
| Levine Mark S. |
Chief Legal Officer |
• – – |
2023-07-26 |
4 |
S |
$21.63 |
$84,725 |
D/D |
(3,917) |
326,774 |
|
- |
|
| Barnett Eva Renee |
Chief Financial Officer |
• – – |
2023-07-19 |
4 |
S |
$24.94 |
$67,962 |
D/D |
(2,725) |
349,863 |
|
- |
|
| Macias William L. |
Chief Medical Officer |
• – – |
2023-07-19 |
4 |
S |
$24.94 |
$10,624 |
D/D |
(426) |
349,725 |
|
- |
|
| Salzmann Peter |
Chief Executive Officer |
• • – |
2023-07-12 |
4 |
S |
$19.73 |
$63,787 |
D/D |
(3,233) |
1,231,136 |
|
- |
|
| Butchko Julia G. |
Chief Development Officer |
• – – |
2023-07-12 |
4 |
S |
$19.73 |
$29,003 |
D/D |
(1,470) |
428,593 |
|
- |
|
| Levine Mark S. |
Chief Legal Officer |
• – – |
2023-04-25 |
4 |
S |
$16.29 |
$42,892 |
D/D |
(2,633) |
330,691 |
|
- |
|
| Macias William L. |
Chief Medical Officer |
• – – |
2023-04-25 |
4 |
S |
$16.29 |
$8,292 |
D/D |
(509) |
350,151 |
|
- |
|
| Barnett Eva Renee |
Chief Financial Officer |
• – – |
2023-04-18 |
4 |
S |
$15.27 |
$52,269 |
D/D |
(3,423) |
352,588 |
|
- |
|
| Butchko Julia G. |
Chief Development Officer |
• – – |
2023-04-18 |
4 |
S |
$15.27 |
$23,577 |
D/D |
(1,544) |
430,063 |
|
- |
|
| Salzmann Peter |
Chief Executive Officer |
• • – |
2023-04-18 |
4 |
S |
$15.27 |
$51,842 |
D/D |
(3,395) |
1,234,369 |
|
- |
|
| Stout Jay S |
Chief Technology Officer |
• – – |
2023-04-17 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
100,000 |
|
- |
|
| Pande Atul |
Director |
– • – |
2023-04-12 |
4 |
A |
$0.00 |
$0 |
D/D |
12,523 |
95,508 |
|
- |
|
| Torti Frank |
Director |
– • – |
2023-04-12 |
4 |
A |
$0.00 |
$0 |
D/D |
121,916 |
515,274 |
|
- |
|
| Butchko Julia G. |
Chief Dev. & Tech. Officer |
• – – |
2023-04-12 |
4 |
A |
$0.00 |
$0 |
D/D |
100,188 |
431,607 |
|
- |
|
| Hughes Douglas J. |
Director |
– • – |
2023-04-12 |
4 |
A |
$0.00 |
$0 |
D/D |
12,523 |
113,755 |
|
- |
|
190 Records found
|
|
Page 3 of 8 |
|
|
